Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07250724 · ClinicalTrials.gov registry record
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
A clinical trial of Clostridioides Difficile Infection Recurrence, sponsored by Bactolife A/S.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT07250724: Recruiting study of Clostridioides Difficile Infection Recurrence, sponsored by Bactolife A/S.
NCT07250724 is a study of Clostridioides Difficile Infection Recurrence that is actively recruiting participants, run by Bactolife A/S. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07250724, a study of Clostridioides Difficile Infection Recurrence, is actively recruiting participants, sponsored by Bactolife A/S.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Hospitals and clinics interested in participating in this multi-site study, please contact the people mentioned under "Contacts and Locations". The goal of this study is to map the risk of having a C. Difficile infection recurrence (rCDI) after being treated with standard-of-care antibiotics for a C. Difficile infection. The main questions it aims to answer are: * What is the recurrence rate of CDI in the 8 weeks following antibiotic treatment for a first recurrence of CDI? * Does toxin levels of Toxin A and/or B from C. Diff. at baseline predict CDI recurrence risk? Participants will: * Undergo standard of care Antibiotic treatment for first recurrence of CDI * Visit their clinic at 4 different visits over a time period of approximately 9 weeks. (Visits can also be performed remote/via phone call.)
Primary Outcome
CDI recurrence will be defined as the development of a new episode of diarrhoea (3 or more loose stools in 24 or fewer hours) associated with a positive stool test for toxigenic C. difficile following clinical cure of the initial CDI episode.
Conditions Studied
Interventions
- OTHER Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment.
Study Locations (1)
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2026-10-15 |
What NCT07250724 shows while recruiting
NCT07250724 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 1 condition, with Clostridioides Difficile Infection Recurrence appearing as the primary indexed condition, and to 1 intervention - of which Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment. is the first listed.
NCT07250724 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT07250724 about?
NCT07250724 is a clinical study titled "C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.". Hospitals and clinics interested in participating in this multi-site study, please contact the people mentioned under "Contacts and Locations". The goal of this study is to map the risk of having a C. Difficile infection recurrence (rCDI) after being treated with standard-of-care antibiotics for a ...
What is the current status of trial NCT07250724?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2026-02-01. Estimated completion is 2026-10-15.
What conditions does trial NCT07250724 study?
This clinical trial studies the following conditions: Clostridioides Difficile Infection Recurrence.
What interventions are being tested in trial NCT07250724?
The interventions under investigation include: Participants that are undergoing standard of care antibiotic treatment for their second C. Diff infection will be followed for 8 weeks after completing antibiotic treatment. (OTHER).
Who is sponsoring clinical trial NCT07250724?
This trial is sponsored by Bactolife A/S, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07250724 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridioides Difficile Infection Recurrence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI